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Angelman syndrome (AS) is a debilitating neurodevelopmental disorder that is
characterized by motor dysfunction, intellectual disability, speech impairment, seizures
and common features of autism spectrum disorders (ASDs). Some of these AS related
phenotypes can be seen in other neurodevelopmental disorders (Williams, 2011; Tan
et al., 2014). AS patients commonly carry mutations that render the maternally inherited
UBE3A gene non-functional. Duplication of the chromosomal region containing the
UBE3A gene is associated with ASDs. Although the causative role for UBE3A gene
mutations in AS is well established, a long-standing challenge in AS research has been
to identify neural substrates of UBE3A, an E3 ubiquitin ligase. A prevailing hypothesis is
that changes in UBE3A protein levels would alter the levels of a collection of protein
substrates, giving rise to the unique phenotypic aspects of AS and possibly UBE3A
associated ASDs. Interestingly, proteins altered in AS are linked to additional ASDs that
are not previously associated with changes in UBE3A, indicating a possible molecular
overlap underlying the broad-spectrum phenotypes of these neurogenetic disorders.
This idea raises the possibility that there may exist a “one-size-fits-all” approach to the
treatment of neurogenetic disorders with phenotypes overlapping AS. Furthermore, while
a comprehensive list of UBE3A substrates and downstream affected pathways should
be developed, this is only part of the story. The timing of when UBE3A protein functions,
through either changes in UBE3A or possibly substrate expression patterns, appears
to be critical for AS phenotype development. These data call for further investigation of
UBE3A substrates and their timing of action relevant to AS phenotypes.
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Angelman syndrome (AS) is a neurodevelopmental disorder that affects one in 15,000 individuals
(Williams et al., 2006). Angelman syndrome is characterized by lack of speech, cognitive
impairments, unusually happy demeanor, motor deficits and seizures, among other symptoms
(Bird, 2014). Notably, Angelman syndrome shows symptomatic overlap with multiple other
neurodevelopmental diseases, including Rett syndrome and Pitt-Hopkins syndrome (Forrest et al.,
2013). While the phenotypic overlap of these diseases is discussed elsewhere (Tan et al., 2014;
Margolis et al., 2015), it is an intriguing hypothesis to consider that converging molecular
mechanisms contribute to a subset of their underlying symptoms.
Maternal loss of chromosomal region 15q11-13 is one cause of Angelman syndrome.
While there are multiple genes in this region, it became apparent that mutations in
UBE3A, a paternally-imprinted gene, are sufficient for causing Angelman syndrome
(Kishino et al., 1997; Matsuura et al., 1997). Phenotype severity is correlated with
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the type of mutation, with the full deletion of 15q11-13 the
most severe and point mutations in UBE3A less severe (Gentile
et al., 2010; Valente et al., 2013). Moreover, while UBE3A
is expressed off the maternal allele in mature neurons, it is
biallelically expressed in most peripheral tissues, in glia, and in
newly born neurons (Albrecht et al., 1997; Gustin et al., 2010;
Judson et al., 2014). Despite this systemic reduction in UBE3A
expression of AS individuals, much research has been focused
on the central nervous system, ignoring peripheral contribution
of reduced UBE3A expression to AS-associated phenotypes.
Interestingly, chromosomal region 15q11-13 is found to be
duplicated in 1–2% of all autism spectrum disorder (ASD) cases,
providing additional evidence for the importance of this region
in developing a functional nervous system (Cook et al., 1997;
Sutcliffe et al., 1997). Indeed, duplications in the chromosomal
region containing only UBE3A have been associated with
developmental delay (Noor et al., 2015).
Mouse models with a maternally-inherited Ube3a deletion
display many Angelman-like phenotypes, including learning and
memory deficits, motor phenotypes, and seizures (Jiang et al.,
1998; Miura et al., 2002). The phenotypes listed here are far
from exhaustive, but have been reviewed elsewhere (Margolis
et al., 2015). These phenotypes are only present when the
deletion is maternally-inherited, with little to no phenotype in
the paternally-deleted animals. In mouse models, not only are
reductions in UBE3A protein expression capable of inducing
neurological deficits, but duplications in UBE3A also show
autism-like phenotypes, such as social and learning and memory
deficits (Smith et al., 2011). The combination of mouse and
human data suggests that UBE3A plays a fundamental and
critical role in regulating pathways important for autism-like
disorders.
UBE3A is an E3 ubiquitin ligase that functions to conjugate
ubiquitin groups to a unique set of proteins (Scheffner et al., 1993;
Huang et al., 1999). Ubiquitinated proteins are then, generally,
targeted for degradation through the ubiquitin-proteasome
system (Ciechanover and Schwartz, 1998). Since mutations in
the catalytic domain of UBE3A are sufficient for development of
Angelman syndrome (Kishino et al., 1997; Matsuura et al., 1997;
Cooper et al., 2004), the lack of ubiquitination and degradation of
UBE3A substrates is predicted to increase these substrate protein
levels. Conversely, increases in UBE3A are expected to decrease
levels of its substrates. It is hypothesized that this alteration
in substrate levels contributes to the variety of phenotypes
associated with AS and, potentially, ASDs.
Given the many neurological phenotypes associated with
changes in UBE3A expression, one major task in the field
has been to identify brain-derived targets as disease-relevant
substrates. A previously published substrate of UBE3A is
Pbl/ECT2, a RhoA guanine nucleotide exchange factor (RhoA
GEF), although the contribution of AS phenotype has not been
interrogated (Reiter et al., 2006). Another published substrate
of UBE3A is the negative synaptic regulator Ephexin5, another
RhoA GEF (Margolis et al., 2010). By reducing Ephexin5 in AS
mice, a recent study found that Ephexin5 does not contribute
to AS related cortical and cerebellar phenotypes such as
vocalization deficits, seizure activity, or motor deficits (Mandel-
Brehm et al., 2015). These results are not surprising considering
that, in the brain, high Ephexin5 expression is restricted to
hippocampus compared to surrounding brain regions when
measured by in situ hybridization (Margolis et al., 2010). Another
substrate reported recently is GAT1, a GABA transporter that
is upregulated in the absence of UBE3A in the cerebellum.
Treatment with THIP, a selective extrasynaptic GABAA receptor
agonist showed the capacity to rescue electrophysiological and
motor deficits (Egawa et al., 2012). Arc, a cytoskeleton-associated
protein known to regulate trafficking of AMPA receptors to
the membrane, is reported to be a substrate of UBE3A (Greer
et al., 2010). Consistent with Arc’s role in contributing to AS
related phenotypes recent data demonstrate that reduction of Arc
levels is capable of ameliorating recovery time after audiogenic
seizures without rescue of ultrasonic vocalizations or motor
behavior deficits (Mandel-Brehm et al., 2015). Despite several
groups having observed varying results regarding Arc’s status
as a direct substrate of UBE3A (Greer et al., 2010; Kühnle
et al., 2013; Mabb et al., 2014; Mandel-Brehm et al., 2015), these
data establish reduction in Arc levels are capable of mitigating
symptoms. Given that these substrates contribute to only a
subset of phenotypes associated with AS, they cannot be the sole
enactors of phenotypic change in AS.
Despite this paucity of confirmed substrates, many non-
substrates, i.e., proteins which are reported to not directly be
regulated by UBE3A in vivo in mammalian tissue, have been
shown to be altered in AS mouse model brains, either at the level
of protein expression or activity, including α1-Na+/K+-ATPase
and CaMKII phosphorylation (Weeber et al., 2003; vanWoerden
et al., 2007; Kaphzan et al., 2013; Mandel-Brehm et al., 2015).
It should be noted that the drosophila homolog to α1-Na+/K+-
ATPase was identified as an interactor with dUBE3A (Jensen
et al., 2013), however this result was not replicated inmouse brain
(Kaphzan et al., 2011). Rescue experiments modulating these
misregulated proteins were done using genetic deletion of the
target proteins or modification of CaMKII phosphorylation sites.
In these cases, a subset of behavioral phenotypes, mostly related
to learning and memory, were ameliorated (van Woerden et al.,
2007; Kaphzan et al., 2013; Mandel-Brehm et al., 2015). Despite
the amelioration of certain phenotypes, none of these studies
reported rescuing all phenotypes observed in AS mouse models.
While the molecular understanding for these disrupted pathways
and their rescuing capacity remains to be fully elucidated, these
data indicate that the development of AS can arise from a
myriad of secondary and tertiary changes downstream of altering
the expression of UBE3A (Figure 1). Interestingly, some of
the proteins shown to be misregulated in AS and/or interact
with UBE3A have also been shown to be disrupted in other
neurodevelopmental disorders, including ASDs in which UBE3A
is not reported to be misregulated (Table 1). These data raise
the possibility that phenotypic overlap between AS and other
neurodevelopmental disorders can be explained by the molecular
overlap in downstream pathways important for nervous system
development. Such overlapping molecular discoveries will be the
first targets toward developing “one size fits all” type therapies
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FIGURE 1 | Diagram of UBE3A substrate cascade to Angelman
syndrome. Angelman syndrome is caused by the pathological loss of
maternal UBE3A protein expression, resulting in the loss of regulation of its
pool of downstream substrates. UBE3A direct interactors/substrates are
labeled as a 1◦ inside a circle. Indirect substrates/changes are labeled as 2◦
inside a circle. Gene products associated with neurodevelopment are in tan
colored circles and associated with Autism spectrum disorders are colored.
Following the loss of UBE3A changes to these 1◦substrates are the initiators
of cascade of events which lead to 2◦ changes. These 2◦ changes can be in
the form of protein-protein interactions, cell biological, electrophysiological,
etc. The convergence of these 2◦ and downstream changes produce
phenotypes characteristic of Angelman syndrome. Given some proteins
known to be misregulated in ASDs are primary or secondary interactors in this
UBE3A-dependent pathway, as indicated by the colored substrates, the
phenotypic overlap between Angelman Syndrome and autism spectrum
disorders it is not surprising. Through the study of UBE3A substrates, more
overlapping molecular changes underlying shared phenotypes may become
apparent.
with the potential of treating similar phenotypes of many
neurodevelopmental disorders associated with AS.
While a comprehensive list of UBE3A substrates and
downstream effected pathways should be developed, this is only
part of the story. The functional interaction between UBE3A
and these pathways will likely vary based on both the expression
profile of UBE3A and the pathways in question.
Both the total protein level and subcellular localization
of UBE3A is altered over development in neurons (Dindot
et al., 2008; Williams et al., 2010; Judson et al., 2014). As
previously mentioned, pyramidal cells in both cortex and
hippocampus express UBE3A from the maternal allele. In intact
TABLE 1 | Possible mammalian UBE3A substrates.
Substrates/Interactors Disease Citation
ANXA1 ASD Shimoji et al., 2009; Correia
et al., 2014
AR ASD Khan et al., 2006;
Henningsson et al., 2009
Arc AS, Fragile X Park et al., 2008; Greer
et al., 2010; Mandel-Brehm
et al., 2015
CDKN1B ASD Mishra et al., 2009; Grey
et al., 2013
DLG1 ASD Matsumoto et al., 2006; Li
et al., 2014
Ephexin5 Epilepsy Margolis et al., 2010;
Veeramah et al., 2013
ESR2 Asperger
syndrome, ASD
Picard et al., 2008;
Chakrabarti et al., 2009
Herc2 AS, ASD Kühnle et al., 2011;
Puffenberger et al., 2012;
Harlalka et al., 2013
mGluR5 AS, Fragile X Dölen et al., 2007; Pignatelli
et al., 2014
SOD1 ASD Mishra et al., 2013; Kovac
et al., 2014
TSC1 AS, TS, ASD Smalley, 1998; Sun et al.,
2015
TSC2 AS, TS, ASD Smalley, 1998; Zheng et al.,
2008; Sun et al., 2015
UBE3A AS, ASD Schwarz et al., 1998; Nurmi
et al., 2001
AS, Angelman Syndrome; TS, Tuberous sclerosis; ASD, Autism spectrum disorder.
brains, maternal UBE3A expression is much higher in mature
neurons as opposed to newly born neurons, both early in
development as well as in adult-born neurons (Dindot et al.,
2008; Judson et al., 2014). Over time, this adult level of
expression is reduced in the mammalian brain during advanced
aging (Williams et al., 2010). Despite this robust age-related
decrease in UBE3A expression, older individuals do not develop
Angelman syndrome. This seemingly contrary idea highlights
the possibility of separating UBE3A functions between the
development of the CNS and in the adult CNS. Not only
are levels of UBE3A consistently reported as changing across
development, the localization of UBE3A shifts to the nucleus
as development progresses. Maternal UBE3A-YFP shows a shift
toward nuclear and synaptic localization later in development
(Judson et al., 2014). To add another layer of complexity,
neuronal activity in culture leads to increased localization of
UBE3A to the nucleus and plasma membrane (Filonova et al.,
2014). Since this change in localization is also activity-regulated,
this indicates that UBE3A interaction with specific substrates
will be activity-regulated as well. Due to neuronal activity and
compartment-specific localization we suggest that sensitivity
of each individual substrate to UBE3A will be altered based
on these parameters, making it possible to miss functionally-
relevant interactions in development- or activity-dependent
scenarios. In fact, measurement of UBE3A’s activity toward
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its substrates in these developmentally-restricted windows, in
various compartments, and under alternative neuronal activity
scenarios has not been done and could elucidate a more complex
layer of regulation by UBE3A not yet appreciated.
The changes in UBE3A localization, expression, and possibly
activity toward distinct targets over development hints that the
timing of treatment in AS will be crucial to the success of the
intervention. The importance of timing is further emphasized
by experiments which re-express UBE3A at different times in
development in AS mouse models: despite correcting the loss
of UBE3A, the number and particular subset of phenotypes that
are ameliorated is variable. It is difficult to ignore the potent
role timing of UBE3A expression may be playing in neuronal
development.
Recent work from the Elgersma lab has returned the wildtype
UBE3A allele to a mouse model of AS at different times in
development using an inducible Cre model (Silva-Santos et al.,
2015). The work indicates that later and later UBE3A expression
resulted in fewer rescued phenotypes. For instance, marble
burying and rotarod deficits were returned to wild type levels
when UBE3A was re-expressed at birth. However, UBE3A no
longer rescued these phenotypes when expressed in adolescence
or adulthood. Interestingly, despite the lack of behavioral rescue,
LTP in the Schaffer collateral was reinstated in both juveniles
and adults. A similar experiment to reactivate UBE3a expression
utilized the mechanism of UBE3A imprinting to induce UBE3A
expression from the paternal allele. The paternal allele is silenced
by the expression of an antisense RNA (UBE3A-ATS) that is
highly expressed to prevent overexpression of UBE3A. When
this transcript is silenced, paternal expression is reinstated up
to 90% of control level. Utilizing antisense oligonucleotides
to disrupt the UBE3A-ATS and induce paternal expression of
UBE3A protein, some phenotypes, such as fear conditioning
and body weight, were ameliorated even upon treatment as
juveniles. However, many phenotypes, including the robust
and reproducible motor phenotypes and marble burying, were
not rescued (Meng et al., 2014). Pharmacological methods of
expressing paternal UBE3A, while successful at initiating protein
expression, have not been characterized to ameliorate Angelman
syndrome phenotypes in vivo (Huang et al., 2012; King et al.,
2013; Powell et al., 2013).
These studies, among others, have illustrated the importance
of the timing of UBE3A expression in the intact animal.While re-
expression of UBE3A later in development is capable of positively
impacting synaptic plasticity, it less effectively rescues behavioral
deficits. Such results question whether the clinically relevant
phenotypes in AS mice are those related to cellular or behavioral
changes. Given the complex nature by which UBE3A affects
nervous system development it is likely that studying UBE3A
interactions and downstream effects relevant to AS pathogenesis
can be best understood through in vivo studies. Systems such as
neuronal culture are more apt to answer questions about general
UBE3A function in the neuron, as developmental dependent
UBE3A effects are stripped of meaning in context of in vivo AS
pathogenesis.
UBE3A is a protein capable of mediating a variety of effects
due to its consistent expression across many cell types and
ages. However, while all functions are potentially important
for fulfilling UBE3A’s role in the body, only a subset of these
functions is especially relevant to AS. Determining the latest
possible point at which UBE3A re-expression is sufficient to
rescue all phenotypes, including behavior, cell biology, and
electrophysiology, will define the crucial window for UBE3A’s
function in AS. This window is the point in which UBE3A is
formative for AS. Therefore, the large list of all UBE3A substrates
can be narrowed to a short list of substrates altered in this
time window and thus more likely to be AS-relevant. Perhaps
more importantly, it is in this time window, and not in others,
that research should be focused in order to determine the most
disease-relevant pathways and mechanisms. This approach for
studying UBE3A contribution to AS provides an opportunity
to explore the overlap with other ASDs, as it is likely that
the developmental restrictions on UBE3A’s contribution to AS
relevant substrates are similar to constraints present in other
ASDs pathogenic proteins.
Mousemodels of AS are an important tool for determining the
UBE3A interactors andmechanisms in this critical window of AS
development. As is well known, studying AS in mouse models
is insufficient for complete understanding the human disease.
In order for the UBE3A-dependent mechanisms elucidated in
mice to have meaning, they must be translated from mouse
to humans, both in respect to subtle changes in mechanism
and to developmental age at which these mechanisms are
occurring.
In humans, many changes likely occur from the loss of UBE3A
at conception to the point at which an affected individual is
diagnosed, and we are very much unaware of the true extent
of these alterations. Therefore, a key question is: when is AS
actually developing in humans?Work done in mouse models will
give a framework for discussing these questions in the context
of human AS, but the timing of human AS still needs to be
established. Reports up to this point indicate that AS begins in
early in life (Bird, 2014), and one hypothesis is that this early
development of AS in mouse will translate to early development
of AS in humans. Given that AS may be taking hold early in
human development, early treatment will be crucial to efficacy
of potential interventions. Therefore, improving methods of AS
detection and removing the delay to diagnosis will be a key
component to taking advantage of these mechanisms for the
successful treatment of AS.
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